On January 7, 2021, PerkinElmer, a global leader committed to innovating for a healthier world, announced that it has that it has entered into a definitive merger agreement to acquire Oxford Immunotec, a global leader of proprietary test kits for latent tuberculosis. Through this acquisition, PerkinElmer will grow its portfolio of advanced infectious disease testing solutions to include tuberculosis detection to better serve customers around the world. The transaction is valued at approximately $591 million.

The proposed transaction is expected to close in the first half of 2021, subject to customary closing conditions.

The WilmerHale team advising PerkinElmer was led by Hal Leibowitz and Chris Barnstable-Brown, and included Mark Nylen and Christopher Gravallese on corporate and M&A matters, Amy Null, Scott Kilgore and Benjamin Kelsey on equity compensation and benefits matters, Julie Hogan Rodgers on tax matters, Bruce Manheim on regulatory matters, Kirk Nahra on privacy matters, and Steven Barrett and Elese Hanson on intellectual property matters.